What Nucoxia-SP Treats: Main Uses and Benefits

Nucoxia-SP is prescribed to help relieve pain, reduce inflammation, and ease muscle stiffness across a range of conditions. Its primary uses include addressing symptoms for adults with rheumatologic conditions and acute pain scenarios.

This medicine is used for the relief of symptoms associated with specific conditions in adults, such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute musculoskeletal pain following injury, and discomfort after dental surgery. The clinical scenarios where it is commonly used focus on conditions causing discomfort and restricted movement.

The primary benefit is centered on the reduction of uncomfortable symptoms, which may support better comfort during daily activities and movement.

Quick Fact: Relief for Joint Pain and Swelling

This medicine works to address the symptoms, offering support for managing your condition.

Nucoxia-SP (a combination product typically containing Etoricoxib and Paracetamol) is subject to strict eligibility rules established by regulatory authorities.

Contraindications (Must Not Use)

Classification	Excluded Populations/Conditions
Hypersensitivity/Allergy	Known allergy to Etoricoxib, Paracetamol, other NSAIDs, or Aspirin (especially if it caused asthma, urticaria, or angioedema).
Cardiovascular Disease	Patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, or uncontrolled hypertension (persisting above 140/90 mmHg).
Organ/GI Impairment	Severe hepatic dysfunction (Child-Pugh 10), severe renal impairment ( CrCl < 30 mL/min), active peptic ulceration, active GI bleeding, or Inflammatory Bowel Disease.
Life Stage	Children and adolescents under 16 years of age. Women who are pregnant or breastfeeding.

Eligibility-Related Restrictions

Use requires special caution and monitoring in patients with a history of heart failure, moderate hepatic or renal impairment, or significant risk factors for cardiovascular events (e.g., diabetes, smoking, hyperlipidaemia). Treatment is allowed only for adults who do not possess any of the listed absolute contraindications.

The official interaction profile of Nucoxia-SP is structured around pharmacodynamic (PD) risks and pharmacokinetic (PK) alterations that are formally documented in regulatory texts.

Pharmacodynamic and Additive Risk

Co-administration with Oral Anticoagulants (such as Warfarin) may cause an officially documented increase in the International Normalized Ratio (INR); the Serrapeptase component may compound the risk of bleeding. Close monitoring of INR is mandatory. Concomitant use with Acetylsalicylic Acid (Aspirin), even at low doses, increases the rate of gastrointestinal complications. The medicine may diminish the antihypertensive effect of Diuretics, ACE Inhibitors, and Angiotensin II Antagonists (AIIAs), and the combination may carry a risk of renal function deterioration in the elderly or volume-depleted patients.

Exposure Modification

The profile highlights significant PK alteration. Exposure to Etoricoxib is substantially decreased by Rifampicin, a strong enzyme inducer, while Etoricoxib increases the exposure of Ethinylestradiol (a component of Oral Contraceptives) by 50% to 60%. Furthermore, co-administration may increase the plasma levels of Lithium or increase the risk of Methotrexate toxicity. These combinations require close monitoring of plasma levels or toxicity indicators as specified in the labeling. Food intake does not affect the pharmacokinetics to a clinically relevant extent.

How Nucoxia-SP Works — Mechanism of Action

The drug's mechanism relies on two complementary pharmacodynamic actions: selective enzyme inhibition and proteolytic hydrolysis. The first component, Etoricoxib, functions as a highly specific inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. By blocking the COX-2 active site, the compound suppresses the synthesis of pro-inflammatory prostaglandins (PGs) at the site of physiological disturbance, chemically limiting the activation and sensitization of peripheral nociceptors. This action modulates the chemical initiation of the inflammatory cascade and reduces peripheral nociceptive signal transduction.

The second component, Serrapeptase, is a systemic proteolytic enzyme that performs hydrolysis on specific excess proteins, polypeptides, and fibrin accumulated within the congested tissue exudate. This enzymatic clearance action helps decrease the viscosity of the fluid and facilitates its resorption via lymphatic drainage, reducing mechanical compression on surrounding tissues caused by edema. The combination demonstrates parallel modulation of both chemical signaling (PG synthesis) and structural components (protein debris clearance) of the physiological inflammatory response.

How Nucoxia-SP is Used

Nucoxia-SP is administered as an oral film-coated tablet and is taken once daily (OD). The medicine should be used at the lowest effective dose and for the shortest duration necessary, with continuous use for chronic conditions requiring periodic re-evaluation. The tablet may be taken with or without food; however, administration without food may result in a faster onset of action when rapid symptomatic relief is required.

Official Dosing Regimens and Maximums

The maximum daily dose for the Etoricoxib component is defined by the condition being treated:

Condition	Starting/Maintenance Dose (Once Daily)	Maximum Daily Dose
Osteoarthritis (OA)	30 mg to 60 mg	60 mg
Rheumatoid Arthritis (RA) & AS	60 mg, may increase to 90 mg	90 mg
Acute Gouty Arthritis	120 mg	120 mg (Max 8 days)
Postoperative Dental Pain	90 mg	90 mg (Max 3 days)

Population-Specific Use and Adjustments

Older Adults typically do not require dosage adjustments. However, specific adjustments are required for liver function: in patients with moderate hepatic impairment (Child-Pugh score 7–9), the total daily dose must not exceed 30 mg once daily. If a scheduled dose is missed, patients should not take a double dose to compensate and must resume their normal schedule the following day.

Research evidence / Overview of studies for Nucoxia-SP

Evidence for Use in Chronic Joint and Musculoskeletal Conditions

Research has explored the use of the medicine’s main component (Etoricoxib) in relation to conditions characterized by fluctuating or episodic manifestations like chronic arthritis. The evidence base comes from large-scale Randomized Controlled Trials (RCTs). These studies explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level in adult patients with confirmed diagnoses of Osteoarthritis (OA), Rheumatoid Arthritis (RA), or Ankylosing Spondylitis (AS). Findings describe patterns observed in the studies where researchers measured differences in functional scores and monitored patient-reported outcomes describing perceived discomfort. The specific contribution of the Serrapeptase component to these chronic outcomes is not fully established in major trials.

---

Evidence for Use in Acute Pain and Tissue Swelling

The medicine was studied for conditions associated with acute or disruptive episodes, such as outcomes following surgery or injury. The research design involved short-term, randomized clinical trials in adults and adolescents. Research examined measurements of acute outcomes related to physical discomfort and associated tissue swelling (edema). Research highlights changes measured during the study period in scores related to a composite measure of patient-reported outcomes. Furthermore, separate studies explored the enzyme component and was observed in some studies to have an association with measurements of reduced swelling and restricted movement. However, evidence quality varies across studies evaluating the enzyme component.

---

What is Still Uncertain About Nucoxia-SP

A key uncertainty relates to the specific fixed-dose combination (FDC) of Etoricoxib and Serrapeptase. The research landscape includes high-level evidence where the NSAID component was studied for outcomes related to physical discomfort, but data are still emerging regarding the incremental effects of adding the systemic enzyme. Long-term effects are not fully established beyond the intermediate duration (e.g., one year) of existing trials. Data for certain groups, such as children or older adults with multiple comorbidities, remain insufficient.

Key Studies & References Serratiopeptidase (Serrapeptase): MedlinePlus Drug Information - National Library of Medicine

Common questions about Nucoxia-SP (FAQ)

---

Q: Can I take Nucoxia-SP if I am already taking an Oral Contraceptive (OC)?

Official product information documents this medicine's potential to significantly increase the body's exposure to Ethinylestradiol, which is a component found in many oral contraceptives. The increase can range from 50% to 60%. This interaction typically indicates the need for close monitoring by a healthcare provider.

---

Q: Is there any food or drink I need to avoid while taking this medication?

According to regulatory documents, the medicine may be taken with or without food, as food intake does not significantly affect the way the medicine works in the body. Regulatory product information does not specify the need to avoid particular drinks or beverages. Documents indicate that taking the tablet without food is associated with a faster onset of action.

---

Q: What should I do if I accidentally take two tablets instead of one?

Official regulatory guidance states that a person should seek immediate medical attention or contact a poison control center if a dose higher than what was prescribed is taken. This guidance applies even if an individual is not feeling any immediate symptoms.

---

Q: How long does it takes for Nucoxia-SP to start relieving pain?

Official information indicates that taking the tablet without food is associated with a faster onset of action. The pharmacokinetic data for the active ingredient, Etoricoxib, indicates that it reaches its maximum concentration in the blood approximately one hour after administration.

---

Q: Is Nucoxia-SP habit-forming or addictive?

Nucoxia-SP, which is a combination of Etoricoxib and Serrapeptase, is classified as a non-narcotic. It is not listed in regulatory schedules for controlled substances, and official documents do not categorize it as having known abuse potential or being habit-forming.

---

Q: Is the medicine safe to cut or crush before taking?

This medicine is manufactured as a film-coated tablet for oral administration. Film-coated tablets are generally intended to be swallowed whole. The official product information does not provide instructions for cutting, crushing, or breaking the tablet.

---

Q: When should I stop taking Nucoxia-SP?

Official safety documents emphasize that this medicine should be used at the lowest effective dose for the shortest duration necessary. For chronic conditions, a healthcare provider must periodically re-evaluate the need for continued therapy. Final decisions regarding the duration of therapy are determined by the healthcare provider.

How to Store and Dispose of Nucoxia-SP?

The official regulatory instructions provide precise constraints on how this medicine must be stored to maintain its integrity and stability, and how it must be safely discarded.

Storage Requirement	Official Constraint
Temperature Limit	Store at a temperature below 30 C (or 86 F).
Environmental Control	Store in a cool and dry place; protect from moisture.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal must adhere to local regulations for pharmaceutical waste. The labeling specifies that unused or expired tablets must be handled carefully to avoid release to the environment.